Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

BackgroundIn patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC). We aimed to investigate whether be...

Full description

Bibliographic Details
Main Authors: Y. Linda Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei-Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi-Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, David J. Pinato, Celina Ang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
immune checkpoint inhibitors
cancer immunotherapy
beta-adrenergic blockade
beta blocker
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1128569/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1128569/full

Similar Items